Mild | Moderate | Severe | Sig. | ||||
---|---|---|---|---|---|---|---|
Total number of patients | 37 | 25 | 40 | ||||
TREC during RSV infection, number of patients | 13 | 10 | 24 | ||||
TREC in neonatal screening cards, number of patients | 32 | 24 | 29 | ||||
Age when RSV diseased - months, median (IQR) | 3 | (1–6) | 3 | (1–5.5) | 2 | (1–4) | p = 0.4a |
Male gender, number (%) | 14 | (38%) | 14 | (56%) | 17 | (43%) | p = 0.4b |
Weight - grams, mean (SD) | 6522 | (2277) | 6748 | (1935) | 5974 | (2065) | p = 0.4c |
Duration of symptoms at admission - days, median (IQR) | 4 | (3–5.25) | 4 | (3.5–5) | 4 | (3–5) | p = 0.9a |
Admission, number (%) | 20 | (54%) | 25 | (100%) | 40 | (100%) | |
Length of stay, median (IQR) | 1 | (0–1) | 1 | (1–3) | 4 | (2.5–5.5) | p < 0.0001d |
Length of stay > 3 days, number (%) | 1 | (3%) | 3 | (12%) | 24 | (62%) | p < 0.0001e |
Respiratory distress | |||||||
SpO2 - % on admission, mean (SD) | 97.4 | (2.6) | 97.9 | (2.3) | 94.7 | (4.5) | p < 0.0001c |
Respiratory rate /min on admission, mean (SD) | 49 | (12) | 58 | (12) | 57 | (10) | p = 0.002c |
Respiratory rate score (max. 8), median (IQR) | 2 | (0.75–4.25) | 4 | (2.5–6) | 4 | (2–6) | p = 0.007a |
p = 0.4d | |||||||
Retraction score (max. 9), median (IQR) | 1 | (0–2) | 4 | (2.25–6) | 2 | (1–4) | p < 0.0001a |
p = 0.003d | |||||||
Wheeze score (max. 8), median (IQR) | 0 | (0–3) | 5 | (4–6) | 2 | (0–4) | p < 0.0001a |
p = 0.0002d | |||||||
m-RDAI, median (IQR) | 6 | (2–8) | 13 | (10.5–16) | 8 | (6–11) | p < 0.0001a |
p < 0.0001d | |||||||
Treatments | |||||||
Fluid supplement, number (%) | 16 | (40%) | |||||
Intravenous fluids, number (%) | 4 | (10%) | |||||
Nasogastric fluid, number (%) | 14 | (35%) | |||||
Oxygen supplement, number (%) | 35 | (88%) | |||||
CPAP, number (%) | 4 | (10%) | |||||
Respirator, number (%) | 0 | (0%) |